右雷佐生

Description

Dexrazoxane · CAS 24584-09-6 · C11H16N4O4. UNII 048L81261F. Melting Point: 191-197 °C; Melting Point: 193 °C; Melting Point: 191 - 197 °C.

Identification

CAS Registry Number	24584-09-6
PubChem CID	71384
Molecular formula	C11H16N4O4
IUPAC name	4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
UNII (FDA)	048L81261F

Computed Descriptors

Molecular Weight	268.27
XLogP3	-1.4
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	3
Exact Mass	268.11715500
Monoisotopic Mass	268.11715500
Topological Polar Surface Area	98.8
Heavy Atom Count	19
Formal Charge	0

Physical & Chemical Properties

Melting Point	191-197 °C
Melting Point	193 °C
Melting Point	191 - 197 °C
Solubility	In water, 10-12 mg/mL at 25 °C
Solubility	1.04e+01 g/L
Solubility	H2O 10 - 12 (mg/mL)
Solubility	0.1 N HCI 35 - 43 (mg/mL)
Solubility	0.1 N NaOH 25 - 34 (mg/mL)
Solubility	10% EtOH 6.7 - 10 (mg/mL)
Solubility	MeOH 1 (mg/mL)

Physical description & handling notes

• Solid
• Crystals from aqueous methanol/ether
• Whitish crystalline powder
• Sparingly soluble
• Slightly soluble in methanol and ethanol. Insoluble in non polar organic solvents.
• Solubility (mg/mL): 35-43 0.1 N HCl, 25-34 0.1 N NaOH, 6.7-10 0.1 M citrate buffer (pH 4), 8.7-13 0.1 M borate buffer (pH 9)

GHS Hazard Classification

Reported hazard statements	H315 (97.7%), H319 (97.7%), H335 (95.3%)

Documented Uses

• For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
• Preparation: A. M. Creighton, GB 1234935 eidem, US 3941790 (1971, 1976 both to Natl. Res. Dev. Corp.)
• Information available in 2005 indicated that Dexrazoxane was used in the manufacture of pharmaceutical preparations in the following countries: Austria, Brazil, Canada, Czech Republic, Denmark, France, Hungary, Israel, Italy, Mexico, Poland, USA (1,2)
• Information available in 2005 indicated that Dexrazoxane hydrochloride was used in the manufacture of pharmaceutical preparations in the following countries: Argentina, Brazil, Denmark, France, Hungary, Italy, Poland, Romania, Russian Federation, United States (1) /Dexrazoxane Hydrochloride/
• Dexrazoxane, an FDA-approved cardioprotective drug, has been successfully used to ameliorate cardiac toxicity seen in anthracycline-based (e.g., doxorubicin, daunorubicin, epirubicin) chemotherapy recipients for cancer, mainly in advanced breast cancer patients, adult patients with soft tissue sarcomas, or small-cell lung cancer. It is used intravenously in conjunction with the anthracycline of choice to decrease the incidence of cardiomyopathy and congestive heart failure.
• Breast Feeding; Lactation; Antineoplastic Agents; Cardioprotectants; Cardiotonic Agents; Enzyme Inhibitors; Topoisomerase II Inhibitors

Synonyms

Dexrazoxane; 24584-09-6; Dextrorazoxane; Dexrazoxano; ICRF-187; Dexrazoxanum; ADR-529; Razoxane, d-; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; Razoxane, (s)-; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; ADR 529; ICRF 187; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; NSC-169780; NSC 169780

Frequently Asked Questions

What are the CAS number and molecular formula of Dexrazoxane?

CAS 24584-09-6; molecular formula C11H16N4O4; molecular weight — g/mol.

What other names is Dexrazoxane known by?

Dexrazoxane, 24584-09-6, Dextrorazoxane, Dexrazoxano, ICRF-187, Dexrazoxanum.

Is Dexrazoxane classified as hazardous?

Hazard statements reported: H315, H319, H335.

What are the key physical properties of Dexrazoxane?

Melting Point: 191-197 °C; Melting Point: 193 °C; Melting Point: 191 - 197 °C; Solubility: In water, 10-12 mg/mL at 25 °C.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.